Methods for detecting and treating cancer
The invention generally features compositions and methods for the diagnosis, treatment, and monitoring of neoplasia in a subject, as well as methods of treatment selection.
1. A method for staging cervical neoplasia in a subject and administering a treatment correlated to a good clinical outcome for the stage of cervical neoplasia, the method comprising:
A) performing an assay to measure the level of a CXCL 12 polypeptide having a molecular weight greater than about 10 kD or 11 kD in the cervical neoplasia;
B) comparing the level of the CXCL 12 polypeptide in the cervical neoplasia to a reference level;
C) classifying the stage of the cervical neoplasia in the subject as a pre-invasive stage or an invasive stage of cervical neoplasia based on the comparison to the reference level wherein an increase in the level of the CXCL12 polypeptide relative to the reference level indicates an invasive stage and a lack of an increase in the level of the CXCL12 polypeptide relative to the reference level indicates a pre-invasive stage; and
D) administering a less aggressive treatment to the subject having a pre-invasive stage of cervical neoplasia, or a more aggressive treatment to the subject having an invasive stage of cervical neoplasia
thereby staging cervical neoplasia in the subject and administering a treatment correlated to a good clinical outcome for the stage of cervical neoplasia.
2. The method of claim 1 , wherein CXCL12 molecular weight is determined in an immunoassay, in an SDS-PAGE assay, by mass spectroscopy, by Western blot, or ELISA.
3. The method of claim 1 , wherein the CXCL 12 polypeptide selectively binds a CXCL12-specific antibody.
4. The method of claim 1 , wherein the CXCL12 polypeptide has at least about 85% identity to the amino acid sequence of any of SEQ ID NOs 2-7.
5. A method for treating cervical neoplasia in a subject, the method comprising:
performing an assay to measure the level of a CXCL 12 polypeptide having a molecular weight greater than about 10 kD or 11 kD in a sample comprising cells from a cervical neoplasia;
comparing the level of the CXCL12 polypeptide in the sample to a first and second reference level;
administering a less aggressive treatment to the subject identified as having a level in the sample above the first reference level and below the second reference level, a pre-invasive cervical neoplasia, or administering a more aggressive treatment to the subject identified as having a level in the sample above both the first and second reference levels, an invasive stage of cervical neoplasia, thereby treating cervical neoplasia in the subject.
6. The method of claim 5 , wherein the first reference level is an increase of less than about 3 fold compared to a control sample.
7. The method of claim 5 , wherein the second reference level is an increase of higher than 3-fold compared to a control sample.